Leerink Partners Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $215
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Walgreens Boots Alliance (WBA) and Bicycle Therapeutics (BCYC)
BofA Securities Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $210
Zoetis Initiated at Neutral by UBS
Zoetis Price Target Announced at $196.00/Share by UBS
Barclays Maintains Overweight on Zoetis, Raises Price Target to $242
Leerink Partners Initiates Zoetis(ZTS.US) With Buy Rating, Announces Target Price $215
Zoetis Analyst Ratings
Leerink Partners Initiates Zoetis(ZTS.US) With Buy Rating, Announces Target Price $215
Barclays Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $242
Barclays Remains a Buy on Zoetis (ZTS)
Piper Sandler Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $210
Piper Sandler Issues a Buy Rating on Zoetis (ZTS)
Jefferies Cuts Zoetis' Price Target to $200 From $210
Morgan Stanley Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $248
TD Cowen Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $214
A Quick Look at Today's Ratings for Zoetis(ZTS.US), With a Forecast Between $210 to $248
TD Cowen Sticks to Their Buy Rating for Zoetis (ZTS)
Barclays Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $242
BofA Securities Maintains Zoetis(ZTS.US) With Buy Rating